Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 7 Endometrial Neoplasms 5 Prostatic Neoplasms 2 Overweight 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycystic Ovary Syndrome 1 Opioid-Related Disorders 1 Lymphoma, Follicular 1 Insulin Resistance 1 Hyperplasia 1 Colorectal Neoplasms 1

Interventions

Rituximab 295 Cyclophosphamide 240 Peripheral Blood Stem Cell Transplantation 114 fludarabine phosphate 110 Filgrastim 93 Etoposide 85 Radiotherapy 81 Lenalidomide 79 Vincristine 78 Prednisone 77 Mycophenolic Acid 66 Doxorubicin 61 Cyclosporine 59 Whole-Body Irradiation 58 Bendamustine Hydrochloride 58 Melphalan 57 Tacrolimus 53 Busulfan 51 fludarabine 50 Cytarabine 48 obinutuzumab 46 Methotrexate 45 Antilymphocyte Serum 43 Bortezomib 42 Methylprednisolone 37 Carmustine 37 sargramostim 36 ibritumomab tiuxetan 32 ibrutinib 30 Dexamethasone 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphoma, Follicular × Tirzepatide × Clear all

NCT06651177 2026-05-22

TAB

University of Cincinnati

Phase 2 Recruiting

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡